

## DAFTAR PUSTAKA

- Arini, Y.D., Rahmawati, F. dan Andayani, T.M., 2016, Faktor Risiko Kejadian Drug Related Problems pada Pasien Penyakit Kronis Rawat Jalan di Poliklinik Penyakit Dalam, *Skripsi*, Universitas Gadjah Mada, Yogyakarta.
- Bhardwaj, P., Deshkar, A.M. dan Verma, R., 2015, Side Effect Encountered in Treatment of Multidrug-Resistant Tuberculosis: A3 Year Experience at First Dots Plus Site of Chhattisgarh, *International Journal of Scientific Study*, **3**(5), 104-107.
- Charlson, M.E., Pompei, P., Ales, K.L., Mackenzie, C.R., 1987, A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies : Development and Validation, *Journal Chronic Disease*, **40**, 373-83.
- Chung, H., Yoon, Y.H. dan Hwang, J.J., 2009, Ethambutol-Induced Toxicity is Mediated by Zinc and Lysosomal Membrane Permeabilization in Cultured Retinal Cells, *Journal Toxicology and Applied Pharmacology*, **23**(5), 163-170.
- Cipolle, R.J., Strand, L.M. dan Morley, P.C., 2012, *Pharmaceutical Care Practice: The Patient-Centered Approach to Medication Management*, 3rd ed., McGraw-Hill Education, New York.
- Dasopang, E.S., Hasanah, F. dan Nisak, C., 2019, Analisis Deskriptif Efek Samping Penggunaan Obat Anti Tuberculosis pada Pasien TBC di RSUD Dr. Pringadi Medan, *Jurnal Penelitian Farmasi Herbal*, **2**(1), 44-49.
- Departemen Kesehatan RI, 2009, *Pedoman Pelayanan Kefarmasian untuk Pasien Pediatri*, Ditjen Bina Kefarmasian dan Alat Kesehatan Departemen Kesehatan Republik Indonesia, Jakarta.
- Dianati, N.A., 2015, Gout and Hyperuricemia, *Journal Majority*, **4**(3), 82-89.
- Dinas Kesehatan DIY, 2018, *Profil Kesehatan D.I.Yogyakarta tahun 2018*, Dinas Kesehatan Daerah Istimewa Yogyakarta, Yogyakarta.
- Eghtedari, B. dan Correa, R., 2020, *Levothyroxine*, StatPearls Publishing, Treasure Island.
- Farhanisa, Untari, E.K. dan Nansy, E., 2016, *Side Effect Incident of Category 1 Antituberculosis Drug (OAT) in Patient with Pulmonary TB in Unit Pengobatan Penyakit Paru-Paru (UP4) West Borneo*, Program Studi Farmasi Fakultas Kedokteran Universitas Tanjungpura, Pontianak.
- Handayani R.S., Gitawati R. dan Muktiningsih S.R., 2006, Eksplorasi Pelayanan Informasi Penyakit Kronik dan Degeneratif, *Majalan Ilmu Kefarmasian*, **3**(1), 38-46.
- Hepler, C.D. dan Strand, L.M., 1990, Opportunities and Responsibilities in Pharmaceutical Care, *American Journal of Hospital Pharmacy*, **47**, 533-543.
- Jan, F., Hassan M., Muhammad, N., Wali, S., Akbar, H.S., Atta, Q.M., Gul, F., 2017, Electrolytes Imbalance Caused by Amikacin in Patients Receiving Multi Drug Resistant-Tuberculosis Treatment at Hazara Region Kpk, Pakistan, *Tuberk Toraks*, **65**(3), 193-201.
- Janan, M., 2019, Faktor-Faktor Risiko yang Berhubungan dengan Peningkatan Prevalensi Kejadian TB MDR di Kabupaten Brebes Tahun 2011-2017, *Jurnal Kebijakan Kesehatan Indonesia*, **8**(2), 64-70.

- Kartasasmita, C.B., 2009, Epidemiologi Tuberkulosis, *Sari Pediatri*, **11**(2), 124-129.
- Kementerian Kesehatan, 2011a, *Modul Penggunaan Obat Rasional*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kementerian Kesehatan, 2011b, *Pedoman Nasional Pengendalian Tuberkulosis*, Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kementerian Kesehatan, 2013, *Petunjuk Teknis Manajemen TB Anak*, Direktorat Jenderal Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kementerian Kesehatan, 2014, *Petunjuk Teknis Manajemen Terpadu Pengendalian Tuberkulosis Resistan Obat*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kementerian Kesehatan, 2015, *Tuberkulosis*, Pusat Data dan Informasi Kementerian dan Kesehatan RI, Jakarta.
- Kementerian Kesehatan, 2016a, *Peraturan Menteri Kesehatan Republik Indonesia Nomor 67 tahun 2016, tentang Penanggulangan Tuberkulosis*, Kementerian Kesehatan republik Indonesia, Jakarta.
- Kementerian Kesehatan, 2016b, *Petunjuk Teknis Manajemen dan Tatalaksana TB Anak*, Direktorat Jenderal Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kementerian Kesehatan, 2017, *Data dan Informasi Profil Kesehatan Indonesia 2017*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Mafukidze, A.T., Calnan, M. dan Furin, J., 2016, Peripheral Neurophaty in Persons with Tuberculosis, *J Clin Tuberc Other Mycobact Dis*, **2**(16), 5-11.
- Musthofa, L.A., 2018, Evaluasi Drug Related Problems Kategori Dosis Berlebih, subdosis, dan interaksi obat pada pasien Tuberculosis Multi Drug Resistant di Rawat Inap RSUD Dr. Moewardi Tahun 2017, *Skripsi*, Fakultas Farmasi Universitas Muhammadiyah Surakarta, Surakarta.
- Narasimhan, P., Wood, J., Raina, M.I., Dilip, M., 2013, *Review Article: Risk Factors for Tuberculosis*, *Pulmonary Medicine*, **13**, 1-11
- Pamungkas, P., Rahardjo, S.S. dan Murti, B., 2018, Evaluation of Multi-Drug Resistant Tuberculosis Predictor Index in Surakarta, Central Java, *Journal of Epidemiology and Public Health*, **3**(2), 263-276.
- PCNE, 2019, *Classification for Drug Related Problems*, Pharmaceutical Care Network European Foundation, Zuidlaren.
- Podder, V. dan Sadiq, N.M., 2020, *Levofloxacin*, StatPearls Publishing, Treasure Island.
- Putri, D.R., 2019, Identifikasi Masalah Terapi Obat pada Pasien Tuberculosis di Instalasi Rawat Inap RSUP. H. Adam Malik, *Skripsi*, Fakultas Farmasi Universitas Sumatera Utara, Medan.
- Qureshi, W., Hassan, G., Kadri, M., Khan, G.Q., Samuel, B., Arshad, A., 2007, Hyperuricemia and Atralgias During Pyrazinamide Therapy in Patients with Pulmonary Tuberculosis, *Labmedicine*, **38**(8), 495-497.

- Raftery, A., Tudor, C., Truee, L., Nawaro, C., 2018, *Panduan Keperawatan untuk Manajemen Efek Samping Pengobatan Tuberkulosis Resisten Obat*, International Council of Nurse, Switzerland.
- Reviono, Kusnanto, P., Eko, V., Pakiding, H., Nurwidiyah, D., 2014, Multidrug Resistant Tuberculosis (MDR-TB): Tinjauan Epidemiologi dan Faktor Risiko Efek Samping Obat Anti Tuberkulosis, *MKB*, **46**(4), 189-196.
- Rojas-Fernandez, C.H., 2014, Can 5-HT3 Antagonist Really Contribute to Serotonin Toxicity? A Call for Clarity and Pharmacological Law and Order, *Drugs Real World Outcomes*, **1**(1), 3-5.
- Rom, W.N. dan Garay, S.M., 2004, *Tuberculosis*, 2nd Ed., 773-789, Lippincott Williams & Wilkins, Philadelphia.
- Rovers, J.P., Currie, J.D., Hagel, H.P., McDonough, R.P., Sobotka, J.L., 2003, *A Practical Guide to Pharmaceutical Care*, 2nd Ed., American Pharmaceutical Association, Washington D.C.
- Rusli, 2018, *Farmasi Klinik*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Sagwa, E., Mantel-Teeuwisse, A.K.M., Ruswa N., Mussa J.P., Pal S., 2012, The Burden of Adverse Events During Treatment of Drug-Resistant Tuberculosis in Namibia, *Southern Mer Review*, **5**(1), 6-13.
- Sarwani, D., Nurlaela, S. dan Zahrotul, I., 2012, Analisis Faktor Multidrug Resistant Tuberculosis (MDR-TB) (Studi Kasus di BP4 Purwokerto), *Jurnal Kesehatan Masyarakat*, **8**(1), 62-68.
- Saukkonen, J.J., Cohn D.L. Jasmer, R.M., Schenker, S., Jereb, J.A., Nolan, C.M., Peloquin, C.A., Gordin, F.M., Nunes, D., Strader D.B., Bernardo, J., Venkataraman, R., Sterling, T.R., 2006, An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy, *Am J Respir Crit Care Med*, **174**, 935-952.
- Sinha, P., Srivastava, G.N., Gupta, A., Anupurba, S., 2017, Association of Risk Factors and Drug Resistance Pattern in Tuberculosis Patients in North India, *J Glob Infect Dis*, **9**(4), 139-145.
- Suparyatmo, J.B., Rina, B., Harsini, Sukma, 2014, Kalium di Multidrug Resistance Tuberculosis dengan Pengobatan Kanamisin, *Indonesian Journal of Clinical Pathology and Medical Laboratory*, **21**(1), 16-19.
- Supriyanto, I., Liung, S., Suprihatini, Ismanto, S.H., 2017, Psychiatric Disorder in Patients with Multidrug Resistant Tuberculosis (MDR-TB) in Sardjito Hospital, Yogyakarta, Indonesia, *J Anal Res Clin Med*, **5**(3), 91-96.
- Surkova, L., Horevich, H.L., Titov, L.P., Sahalchyk, E., Arjomandzadegan, M., Alinejad, S., Sadrina, M., 2012, A Study on Demographic Characteristics of Drug Resistant Mycobacterium Tuberculosis Isolates in Belarus, *International Journal of Mycobacteriology*, **1**, 75-81.
- Tama, T.D., Adisasmita, A.C. dan Burhan, E., 2016, Indeks Massa Tubuh dan Waktu Terjadinya Konversi Sputum pada Pasien Tuberkulosis Paru BTA Positif di RSUP Persahabatan Tahun 2012, *Jurnal Epidemiologi Kesehatan Indonesia*, **1**(1), 1-8.
- Tamsil, T.A., Nawas, A. dan Sutoyo, D.K., 2014, Pengobatan Multidrug Resistant Tuberculosis (MDR-TB) dengan Paduan Jangka Pendek, *J Respir Indo*, **34**(2), 109-121.

- Tegegne, B.S., Mengesha, M.M., Teferra, A.A., Awoke, M.A., Habtewold, T.D., 2018, Association between Diabetes Mellitus and Multi-Drug-Resistant Tuberculosis: Evidence from a Systematic Review and Meta-Analysis, *Syst Rev*, **7**, 161.
- Tola, H.H., Naieni, K.H., Lejisa, T., Mansournia, M.A., Yaseri, M., Tesfaye, E., Mola, M., 2019, Is Hypothyroidism Rare in Multidrug Resistance Tuberculosis Patients on Treatment? A Systematic Review and MetaAnalysis, *Plos One*, **14**(6), 1-18.
- Torres-Espindola, L.M., Dementrio-Rios, J., Carmona-Aparicio, L., Galvan-Diaz, C., Perez-Garcia, M., Chavez-Pacheco, J.L., Granados-Montiel, J., Torres-Ramirez de Arellano, I., Aquino-Galvez, A., Castillejos-Lopez, M.J., 2019, Comorbidity Index as a Predictor of Mortality in Pediatric Patients with Solid Tumors, *Frontiers in Pediatrics*, **7**, 1-7.
- Tripathi, R.P., Tewari, N., Dwivedi, N., Tiwari, V. K., 2005, Fighting Tuberculosis: an Old Disease with New Challenges, *Medical Research Reviews*, **25**, 93-131.
- Untari, S.D., 2018, Evaluasi Rasionalitas Penggunaan Obat Anti Tuberkulosis pada Pasien Rawat Inap TB MDR (Tuberculosis Multi Drug Resistance) Dewasa di RSUD Dr. Moewardi Surakarta Tahun 2016, *Skripsi*, Fakultas Farmasi Universitas Muhammadiyah Surakarta, Surakarta.
- Waleekhachonloet, O., Limwattananon, C. dan Rattanachotphanit, T., 2019, Coprescription of QT Interval-Prolonging Antipsychotics with Potentially Interacting Medications in Thailand, *Therapeutic Advances in Drug Safety*, **10**, 1-14.
- Widiastuti, E.N., Subronto, Y.W. dan Pramono, D., 2017, Determinan Kejadian Multi-Drug Resistant Tuberculosis di Rumah Sakit Dr. Sardjito Yogyakarta, *Berita Kedokteran Masyarakat*, **33**(7), 325-330.
- World Health Organization, 2010, *Treatment of Tuberculosis Guidelines*, 4th Ed., WHO, Geneva, Switzerland.
- World Health Organization, 2014, *WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis*, WHO, Jenewa.
- World Health Organization, 2017, *Global Tuberculosis Report 2017*, WHO, Jenewa.
- World Health Organization, 2018, *Global Tuberculosis Report 2018*, WHO, New York.
- World Health Organization, 2019, *WHO Consolidated Guideline on Drug-Resistant Tuberculosis Treatment*, WHO, Switzerland.
- Zhang, L., Meng, Q., Chen, S., Zhang, M., Chen, B., Wu, B., Yan, G., Wang, X., Jia, Z., 2018, Treatment Outcomes of Multidrug-Resistant Tuberculosis Patients in Zhejiang, China, 2009-2013, *Clinical Microbiology and Infection*, **24**, 381-388.